Kava

Related Terms

11-Methoxy-5,5-hydroxydihydrokawain, 6-dihydroyangonin, alkaloids, antares, ava, ava pepper, ava pepper shrub, ava root, awa, bornyl cinnamate, Cavain, chalcone methylesters, desmethoxyyangonin, dihydrokavain, dihydrokawain (DHK), dihydromethysticin (DMH), (+)-dihydrokawain-5-ol, Fijian kava, flavokavine A, flavokavine B, flavonoids, gea, gi, grog, intoxicating long pepper, intoxicating pepper, kao, kava kava extract LI 140, kava kava rhizome, kava root, kavain, kavakava, kavalactones, kavapiper, kavapyrones, kavarod, kavasporal forte, kave-kave, kawa, kawa kawa, kawa pepper, Kawa Pfeffer, kawain, kew, lactones, LI150, long pepper, Macropiper latifolium, malohu, maluk, maori kava, meruk, methysticin, milik, pepe kava, Piper methysticum, Piper methysticum G.Forst, Piperis methystici rhizoma, pipermethystine, pyrones, Rauschpfeffer, rhizoma Piperis methystici, Rhizome Di Kava-Kava sakaua, sakau, tonga, WS 1490, wurzelstock, yagona, yangona, yangonin, yaqona, yongona.

Background

Drinks made from the dried roots of the kava shrub have been used in the South Pacific for hundreds of years and in Europe since the 1700s. The drink is reported to have pleasant mild effects similar to those of alcoholic drinks. Kava use has spread in Aboriginal communities in Australia over the last 20 years, where it is often combined with alcohol. In Fiji, kava is still used during welcome and religious ceremonies.
Studies report that kava may help treat anxiety in as few as 1-2 doses, with continued improvements over 1-4 weeks. Early evidence suggests that kava may be as effective as antianxiety drugs like benzodiazepines. Kava preparations were widely used in Europe and the United States to relieve anxiety but have been withdrawn in several European markets and Canada due to safety concerns.
There is promising evidence supporting the use of kava in improving cognition, depression, and hot flashes. More research is needed to make firm conclusions.
Kava has been used as a treatment for insomnia. However, many experts believe that kava may lack effectiveness for this purpose. Chronic or heavy use of kava has been linked to changes in the nervous system or skin, as well as high blood pressure in the lung arteries.
There is widespread concern that kava may be harmful to the liver. More than 30 cases of liver damage have been reported in Europe, including liver swelling, inflammation, scarring, dysfunction, and failure, as well as some reports of death. However, some experts maintain that kava is safe in most people when used in recommended doses. It is unclear what dose or length of use may be lead to liver damage. This remains an area of controversy.

Evidence Table

These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. GRADE *
These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. GRADE *


Many studies report that kava is moderately effective for relieving anxiety. Kava has been found to promote significant improvement of anxiety symptoms. Early evidence suggests that kava may be as effective as antianxiety drugs like benzodiazepines. Kava's effects may be similar to the prescription drug buspirone (Buspar?). The German expert panel Commission E has approved kava for anxiety, stress, and restlessness.

 A


Many studies report that kava is moderately effective for relieving anxiety. Kava has been found to promote significant improvement of anxiety symptoms. Early evidence suggests that kava may be as effective as antianxiety drugs like benzodiazepines. Kava's effects may be similar to the prescription drug buspirone (Buspar?). The German expert panel Commission E has approved kava for anxiety, stress, and restlessness.

 A


There are conflicting results on the effectiveness of kava for cognitive aspects such as memory, attention, and reaction time. It has been suggested that kava may not have sedative effects at recommended doses, which may be an advantage over some drugs. There is early evidence that kava may improve mental performance. More research is needed before firm conclusions can be made.

 C


There are conflicting results on the effectiveness of kava for cognitive aspects such as memory, attention, and reaction time. It has been suggested that kava may not have sedative effects at recommended doses, which may be an advantage over some drugs. There is early evidence that kava may improve mental performance. More research is needed before firm conclusions can be made.

 C


There is some evidence that kava may help relieve depression. Kava has been used in combination with St. John's wort in people with depression and anxiety. Further research is needed in this area.

 C


There is some evidence that kava may help relieve depression. Kava has been used in combination with St. John's wort in people with depression and anxiety. Further research is needed in this area.

 C


Early study suggests that kava may significantly improve hot flashes, compared to placebo. High-quality research is needed before conclusions can be made.

 C


Early study suggests that kava may significantly improve hot flashes, compared to placebo. High-quality research is needed before conclusions can be made.

 C


There have been some reports that kava may have sedative effects. However, there is conflicting evidence. Some studies have found a lack of sedation with kava use. Early research reported that kava lacked significant effects in people with insomnia. More research is needed to determine whether kava is effective for this condition.

 C


There have been some reports that kava may have sedative effects. However, there is conflicting evidence. Some studies have found a lack of sedation with kava use. Early research reported that kava lacked significant effects in people with insomnia. More research is needed to determine whether kava is effective for this condition.

 C


Early research suggests that kava and valerian may improve health by reducing stress and insomnia caused by stress. More research is needed to confirm these results.

 C


Early research suggests that kava and valerian may improve health by reducing stress and insomnia caused by stress. More research is needed to confirm these results.

 C


It is unclear whether kava is safe or effective for use in people with Parkinson's disease. Kava may increase periods of reduced mobility in people taking levodopa and may cause a semicomatose state when levodopa is taken with alprazolam. More research is needed in this area to make a firm conclusion.

 D


It is unclear whether kava is safe or effective for use in people with Parkinson's disease. Kava may increase periods of reduced mobility in people taking levodopa and may cause a semicomatose state when levodopa is taken with alprazolam. More research is needed in this area to make a firm conclusion.

 D
* Key to grades

A: Strong scientific evidence for this use
B: Good scientific evidence for this use
C: Unclear scientific evidence for this use
D: Fair scientific evidence for this use (it may not work)
F: Strong scientific evidence against this use (it likley does not work)
* Key to grades

A: Strong scientific evidence for this use
B: Good scientific evidence for this use
C: Unclear scientific evidence for this use
D: Fair scientific evidence for this use (it may not work)
F: Strong scientific evidence against this use (it likley does not work)

Tradition / Theory

The below uses are based on tradition, scientific theories, or limited research. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. There may be other proposed uses that are not listed below.

Dosing

Adults (18 years and older)
Kava extract taken by mouth as 300 milligrams daily in three divided doses has been reported as effective and well tolerated. Typical doses range from 50 to 280 milligrams of kava lactones daily as a single dose or divided doses.
To treat anxiety, doses range from 50 to 400 milligrams daily. A dose of 100 milligrams has been taken by mouth three times daily. A dose of 50 milligrams of WS 1490 has been taken by mouth three times daily for up to four weeks. Two 50-milligram capsules have been taken by mouth the evening before surgery, followed by two 50-milligram capsules taken by mouth 60 minutes before surgery. A dose of 400 milligrams of Kava-Kava LI150 has been taken by mouth daily. A capsule containing 150 milligrams of kava kava rootstock (Kavosporal? forte) has been taken by mouth for seven days. Five tablets, each containing 50 milligrams of kavalactones, have been taken by mouth in three divided doses (two in the morning, two in the afternoon, and one in the evening) daily for one week. A dose of 400 milligrams of kava has been taken by mouth daily for eight weeks. A one-time dose tablet of 60 milligrams of kavalactones has been taken by mouth. Doses of 50-7,980 milligrams of dry kava extract have been taken by mouth daily for 3-24 weeks. A dose of 280 milligrams of kava has been taken by mouth daily for four weeks. Kava extract-pure? containing 140-280 milligrams of kavapyrones has been taken by mouth daily for four weeks. P. methysticum LI 50 extract has been taken by mouth daily for eight weeks.
To improve cognition, a one-time dose of three kava tablets (each containing 60 milligrams of kavalactones) has been taken by mouth. The following doses have been taken by mouth: 300-600 milligrams of kava extract, 450 milligrams per liter of kawain and dihydrokawain, 30 grams of kava powder, one gram of kava per kilogram, and 200-600 milligrams of synthetic kava. Doses of 100-440 grams of kava powder have been taken by mouth weekly.
To treat depression, five tablets (each containing 50 milligrams of kavalactones) have been taken by mouth in three divided doses (two in the morning, two in the afternoon, and one in the evening) daily for one week.
To improve mood, a single dose of 300 milligrams of kava extract has been taken by mouth.
To treat hot flashes, 100 milligrams of kava has been taken by mouth daily.
To treat insomnia, kava special extract WS 1490 has been taken by mouth in daily doses of 200 milligrams. A dose of 120 milligrams of kava has been taken by mouth daily for six weeks. One soft gel capsule containing 100 milligrams of kavalactones has been taken by mouth three times daily.

Safety

The U.S. Food and Drug Administration does not strictly regulate herbs and supplements. There is no guarantee of strength, purity or safety of products, and effects may vary. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy. Consult a healthcare provider immediately if you experience side effects.

Interactions

Interactions with Drugs
Kava may increase the risk of bleeding when taken with drugs that increase the risk of bleeding. Some examples include aspirin, anticoagulants (blood thinners) such as warfarin (Coumadin?) or heparin, antiplatelet drugs such as clopidogrel (Plavix?), and nonsteroidal anti-inflammatory drugs such as ibuprofen (Motrin?, Advil?) or naproxen (Naprosyn?, Aleve?).
Kava may interfere with the way the body processes certain drugs using the liver's cytochrome P450 enzyme system. As a result, the levels of these drugs may be increased in the blood and may cause increased effects or potentially serious adverse reactions. People using any medications should check the package insert and speak with a qualified healthcare professional, including a pharmacist, about possible interactions.
Kava may increase the sedative effects caused by some drugs. Examples include benzodiazepines such as lorazepam (Ativan?) or diazepam (Valium?), barbiturates such as phenobarbital, narcotics such as codeine, some antidepressants (including monoamine oxidase inhibitors [MAOIs] and selective serotonin reuptake inhibitors [SSRIs]), and alcohol. Caution is advised while driving or operating machinery.
Kava may also interact with ACE inhibitors, agents that are eliminated by the kidneys, agents that harm the liver, agents that promote urination, agents that regulate heart rate, agents that treat blood disorders, alcohol, anesthetics, anti-anxiety agents, anticancer agents, birth control, buspirone, central nervous system (CNS) depressants, CYP2D6 substrates, CYP2E1 substrates, CYP3A substrates, digoxin, dopamine agonists, dopamine antagonists, eye agents, heart agents, hormonal agents, mood stabilizers, nervous system agents, opipramol, pain relievers, skin agents, and stomach agents.

Attribution

This information is based on a systematic review of scientific literature edited and peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com).

Bibliography

Bodkin R, Schneider S, Rekkerth D, et al. Rhabdomyolysis associated with kava ingestion. Am.J.Emerg.Med. 2012;30(4):635-3.
Buettner C, Mukamal KJ, Gardiner P, et al. Herbal supplement use and blood lead levels of United States adults. J.Gen.Intern.Med. 2009;24(11):1175-1182.
Freshour JE, Odle B, Rikhye S, et al. Coltsfoot as a potential cause of deep vein thrombosis and pulmonary embolism in a patient also consuming kava and blue vervain. J.Diet.Suppl 2012;9(3):149-154.
Kelley KW and Carroll DG. Evaluating the evidence for over-the-counter alternatives for relief of hot flashes in menopausal women. J.Am.Pharm.Assoc.(2003.) 2010;50(5):e106-e115.
Lakhan SE and Vieira KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr.J. 2010;9:42.
Laporte E, Sarris J, Stough C, et al. A. Neurocognitive effects of kava (Piper methysticum): a systematic review. Hum.Psychopharmacol. 2011;26(2):102-111.
Li XZ and Ramzan I. Role of ethanol in kava hepatotoxicity. Phytother.Res. 2010;24(4):475-480.
Sarris J and Kavanagh DJ. Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. J.Altern.Complement Med. 2009;15(8):827-836.
Sarris J, Kavanagh DJ, Byrne G, et al. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. Psychopharmacology (Berl) 2009;205(3):399-407.
Sarris J, Kavanagh DJ, Deed G, et al. St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial. Hum.Psychopharmacol. 2009;24(1):41-48.
Sarris J, Laporte E, and Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust.N.Z.J.Psychiatry 2011;45(1):27-35.
Sarris J, Panossian A, Schweitzer I, et al. Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence. Eur.Neuropsychopharmacol. 2011;21(12):841-860.
Sarris J, Scholey A, Schweitzer I, et al. The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study. Hum.Psychopharmacol. 2012;27(3):262-269.
Teschke R, Fuchs J, Bahre R, et al. Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment. J.Clin.Pharm.Ther. 2010;35(5):545-563.
Teschke R, Genthner A, and Wolff A. Kava hepatotoxicity: comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures. J.Ethnopharmacol. 6-25-2009;123(3):378-384.